The IL-6 inhibitor ziltivekimab has been evaluated in the phase 2 RESCUE trial, which enrolled patients with chronic kidney disease (CKD) and persistent inflammation (high-sensitivity CRP ≥2 mg/L), a population at high atherosclerotic risk but without confirmed CAD.12 Ziltivekimab induced a dose-dependent reduction in high-sensitivity CRP and other inflammation- and thrombosis-related biomarkers, with no significant safety concerns. Here, IL6 is linked to coronary artery disorder.